How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.

ABSTRACT:

Background

Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness results. This study aims to examine current practices of modeling companion biomarkers when assessing the cost-effectiveness of targeted cancer therapies. It investigates the current methods in modeling the characteristics of companion diagnostics based on existing economic evaluations of biomarker-guided therapies in cancer.

Methods

A literature search was performed using Medline, Embase, EconLit, Cochrane library for economic evaluations of biomarker-guided therapies with companion diagnostics in cancer. Preferred Reporting Items of Systematic Reviews an

SUBMITTER: Seo MK 

PROVIDER: S-EPMC8408935 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature